▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1681 by analyst upside · 2026-08-13
PTCT
PTC Therapeutics, Inc.
Healthcare · Market Cap $6B · P/E 0x
ANALYST PRICE TARGET
+34.7%
implied upside to consensus target
Current Price $72.64
Consensus Target $97.86
Bull Target $130.0
Bear Target $70.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
7
Hold
2
Sell
1
52-Week Low $45.42
52-Week High $90.87
YTD Return -5.3%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) N/A
Forward P/E 29.1x
EPS (TTM) $-0.67
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1.0B
Profit Margin -3.8%
52-WEEK RANGE
52-Week Low $45.42
52-Week High $90.87
Current Price $72.64
Bear Target $70.0
Bull Target $130.0
● Now $72.64 ● Target $97.86
TRADING DATA
Avg Volume 1.7M
YTD Return -5.3%
Analyst Count 14
Consensus Buy
Upside to Target +34.7%
Last Updated 2026-08-13

ANALYST SUMMARY

PTC Therapeutics, Inc. (PTCT) is currently trading at $72.64 with a Wall Street consensus price target of $97.86, implying potential upside of 34.7% over the next 12 months. 14 analysts currently cover PTCT, with a consensus rating of Buy - 79% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $130.0, while the most cautious has a target of $70.0.

PTCT operates in the Healthcare sector with a market capitalisation of $6B. The stock is down 5.3% year-to-date and is currently trading near the upper end of its 52-week range of $45.42 – $90.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CAI +21.3%
Caris Life Sciences, Inc.
$6B · P/E 2.3x · Buy
GRFS +37.0%
Grifols, S.A.
$5B · P/E 10.4x · Buy
HNGE +21.8%
Hinge Health, Inc.
$7B · P/E 10.8x · Buy
ACAD +13.8%
ACADIA Pharmaceuticals Inc.
$5B · P/E 13.2x · Buy
INDV +26.5%
Indivior Pharmaceuticals, Inc.
$5B · P/E 13.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PTCT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Jefferies ↑ Upgrade
Hold → Buy 2026-05-27 50% win rate (6 calls)
TD Cowen ↑ Upgrade
Hold → Buy 2026-05-08 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-05-08 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-05-08 Building track record
Jefferies ↓ Downgrade
Buy → Hold 2026-03-30 50% win rate (6 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-02-23 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-02-20 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-02-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
48
out of 100
Coverage depth
21/30
Consensus clarity
13/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →